Inhibitors

Soyacerebroside I
Catalog No: CFN99242

Soyacerebroside I demonstrates a potent tyrosinase inhibitory activity. Soyacerebroside I shows anti-inflammatory activity, it can inhibit the accumulation of pro-inflammatory iNOS protein and reduce the expression of COX-2 protein in LPS-stimulated RAW264.7 macrophages. Soyacerebrosides I and II have modulating the cellular immune response effects, they show obvious inhibitory activity on IL-18 secretion in human peripheral blood mononuclear cells (PBMC).

Blumeatin
Catalog No: CFN99278

Blumeatin has antioxidant properties, free radical scavenging activity,and has xanthine oxidase (XO) inhibitory activity. Blumeatin can protect liver against injury induced by CCl4 and TAA, it can inhibit the increase of serum alanine aminotransferase (AAT) and liver triglyceride and increased serum triglyceride, beta-lipoprotein, and liver glycogen content in CCl4-intoxicated rats, and can shorten the pentobarbital sleeping time in CCl4-intoxicated mice. Blumeatin can promote adipocyte differentiation as characterized by increased triglyceride levels in 3T3L1 cells, also can enhance the accumulation of lipid droplets and induced upregulation of the expression of the adipocyte-specific genes aP2 and GLUT4.

Acetylepipodophyllotoxin
Catalog No: CFN99279

Acetylepipodophyllotoxin has insecticidal activity.

Cannabidiolic acid
Catalog No: CFN99356

Cannabidiolic acid inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. Cannabidiolic acid displays significantly greater potency at inhibiting vomiting in shrews and nausea in rats, and at enhancing 5-HT(1A) receptor activation; it also selectively inhibits cyclooxygenase (COX)-2 activity with an IC(50) value around 2 microM, has 9-fold higher selectivity than COX-1 inhibition. Cannabidiolic acid and cannabidiol have inhibitory actions on the intestines of S. murinus that are not neuronallymediated or mediated via CB1 or CB2 receptors.

Axillaridine A
Catalog No: CFN99386

Axillaridine A is a new cholinesterase inhibitors, it may act as potential leads in the discovery of clinically useful inhibitors for nervous-system disorders, particularly by reducing memory deficiency in Alzheimer’s disease patients by potentiating and effecting the cholinergic transmission process. (+)-Axillaridine A has significant activity as antiestrogen binding site (AEBS)-inhibitory agents.